Pharmacologic inhibition of integrin shows anti-lymphoma effect in PTCL-NOS and ALCL mouse models. (A) Tumor volume (measured by AUC, from day 1 to day 20) in OCI-Ly12 xenografted mice treated with vehicle vs cilengitide. (B) DNA-binding capacity of NF-κB family members assessed by an enzyme-linked immunosorbent assay–based assay in extracted nuclear fractions of disaggregated lymphoma tissues from the tumors obtained in panel A. (C) Microvascular lumen (by intravascular isolectin) and apoptotic bodies (by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay) in representative tissue sections of the tumors from vehicle- and cilengitide-treated OCI-Ly12 mice. Scale bar, 25 μm (upper) and 100 μm (lower). The white lines show representative maximum lumen size measurements. (D-E) AUC of tumor growth of ALCL ALK-negative (D) and ALCL ALK-positive (E) patient-derived lymphomas in NSG mice treated with vehicle vs cilengitide. (F) Cartoon representation of TH regulation of TCL prosurvival pathways via the activation of αvβ3 integrins.